四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格

阿斯达克财经04-25

四环医药(00460.HK) 公布，4月23日，旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格，且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2430479846?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg","is_english":false,"pubTime":"2024-04-25 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2430479846","market":"fut","top_or_hot":-1,"title":"四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格","media":"阿斯达克财经","content":"<div>\n<p>四环医药(00460.HK) 公布，4月23日，旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格，且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1345132&catg=4&source=AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 17:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1345132&catg=4&source=AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>四环医药(00460.HK) 公布，4月23日，旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格，且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1345132&catg=4&source=AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1345132&catg=4&source=AAFN","article_id":"2430479846","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430479846","pubTimestamp":1714037160,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"四环医药(00460.HK) 公布，4月23日，旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格，且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","00460":"四环医药","BK1600":"工业大麻"},"translate_title":"Sihuan Pharmaceutical (00460. HK) 's three insulin aspart series products have been qualified for selection in the special continuous procurement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"四环医药(00460.HK) 公布，4月23日，旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格，且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430479846"}